Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Genetic factors underlying the risk of bortezomib induced peripheral neuropathy in multiple myeloma patients.

Haematologica - 1 Nov 2011

Corthals Sophie L, Kuiper Rowan, Johnson David C, Sonneveld Pieter, Hajek Roman, van der Holt Bronno, Magrangeas Florence, Goldschmidt Hartmut, Morgan Gareth J, Avet-Loiseau Hervé

Abstract excerpt

Bortezomib induced peripheral neuropathy is a dose-limiting side effect and a major concern in the treatment of multiple myeloma. To identify genetic risk factors associated with the development of this side effect in bortezomib treated multiple myeloma patients, a pharmacogenetic association study was performed using a discovery set (IFM 2005-01; n = 238) and a validation set (HOVON65/GMMG-HD4 and a Czech...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antineoplastic Agents
Share to Boronic Acids

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Bortezomib

Share to Multiple Myeloma

Share to Peripheral Nervous System Diseases

Share to Polymorphism, Single Nucleotide

Share to Pyrazines

Share to Risk Factors

Source

Open in PubMed Open full text

Identifiers

PMID: 21791469
DOI: 10.3324/haematol.2011.041434
PMCID: PMC3208695

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Genetic factors underlying the risk of bortezomib induced peripheral neuropathy in multiple myeloma patients.PMID 21791469Read ↗

Bortezomib-induced peripheral neuropathy: A genome-wide association study on multiple myeloma patients.Semantic proximity Read ↗

Impact of Genetic Polymorphisms on Bortezomib-Induced Peripheral Neuropathy in Multiple Myeloma: A Systematic Review and Bioinformatics Analysis.Semantic proximity Read ↗

Mechanisms of peripheral neuropathy associated with bortezomib and vincristine in patients with newly diagnosed multiple myeloma: a prospective analysis of data from the HOVON-65/GMMG-HD4 trial.Semantic proximity Read ↗

Genetic Susceptibility to Bortezomib-Induced Peripheral Neuroropathy: Replication of the Reported Candidate Susceptibility Loci.Semantic proximity Read ↗

Prediction of peripheral neuropathy in multiple myeloma patients receiving bortezomib and thalidomide: a genetic study based on a single nucleotide polymorphism array.Semantic proximity Read ↗

Chemotherapy-induced peripheral neuropathy: evidence from genome-wide association studies and replication within multiple myeloma patients.Semantic proximity Read ↗

A Genome-Wide Association Study Identifies a Novel Locus for Bortezomib-Induced Peripheral Neuropathy in European Patients with Multiple Myeloma.Semantic proximity Read ↗

Genetic risk factors for bortezomib-induced peripheral neuropathy in an Asian population: A genome-wide association study in South KoreaSemantic proximity Read ↗

A genetic variant study of bortezomib-induced peripheral neuropathy in Chinese multiple myeloma patients.Semantic proximity Read ↗

Genetic factors underlying the risk of thalidomide-related neuropathy in patients with multiple myeloma.Semantic proximity Read ↗

Genetic variation associated with bortezomib-induced peripheral neuropathy.Semantic proximity Read ↗

Genetic Risk Factors for Bortezomib-induced Neuropathic Pain in an Asian Population: A Genome-wide Association Study in South Korea.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.